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Importance. Depression is a common co-morbidity for people living with HIV (PLWH) and is associated with elevated
plasma HIV RNA levels. While depression correlates with deficits in antiretroviral (ARV) adherence, little data exist to
inform the relationship between depression and HIV vial load more broadly.
Objective. To examine the relationship between depression and viral load in the African Cohort Study (AFRICOS) inde-
pendently of ARV adherence.
Design. PLWH in Kenya, Uganda and Tanzania underwent screening for depression using the Center for
Epidemiologic Studies Depression Scale (CESD) upon enrollment at AFRICOS HIV care sites.
Setting. AFRICOS is an ongoing prospective longitudinal cohort study enrolling HIV-infected adults at HIV care cen-
ters including sites in Kenya, Tanzania and Uganda. These sites are administered by President’s Emergency Plan For
AIDS Relief programs.
Participants. HIV+ individuals were eligible if they were at least 18 years old, receiving HIV care at the enrolling clinic
and consented to data and specimen collection.
Main outcome measure. CESD.
Results. Among 2307 participants, 18–25% met the CESD threshold for depression. Depression was associated with
decreased ARV adherence (OR 0.59, p = 0.01). Higher scores on three CESD items were significantly associated with
209–282% higher viral load, independently of ARV adherence among participants on ARVs ⩾6 months.
Conclusions. PLWH had high prevalence of depression on the CESD. Diverse depression symptoms were independ-
ently associated with increases in viral load, underscoring the need for comprehensive treatment of depression.
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Introduction
The strong association between HIV infection and
depression is well established. In high-income coun-
tries, the estimated prevalence of depression among
people living with HIV (PLWH) is approximately
25%, three times higher than HIV-uninfected indivi-
duals (Do et al., 2014). The proportion of HIV-infected
individuals with depression may be even higher in
low- and middle-income countries (Lowther et al.,
2014) where mental health care is scarce (World
Health Organization, 2016) and the majority of
PLWH reside. Depression prevalence studies produce
variable results, but reach as high as 63% among
PLWH in sub-Saharan Africa (Bernard et al., 2017).
HIV viral load and depression: association with
antiretroviral (ARV) adherence
One of the most common rationales for addressing
depression in the setting of HIV is that depressed indi-
viduals are less likely to adhere to ARV regimes when
compared with PLWH who are not depressed. The
presence of depressive symptoms is associated with
42% lower likelihood of achieving ARV adherence
(Uthman et al., 2014). Given the strong effect of ARVs
on HIV viral load, adherence has been a primary
focus for studies of depression among PLWH. This
emphasis is reflected in mental health treatment stud-
ies with PLWH, where improved ARV adherence is
often a primary objective of behavioral/psychosocial
interventions. However, we may be unable to appreci-
ate the more complex interactions between depression
and HIV viral load, and, critically, opportunities to
improve the overall mental and physical health of
PLWH when a focus on the impact of depression on
ARV adherence eclipses the other roles depression
may play in the pathogenesis of HIV.
HIV viral load and depression: associations that
do not involve ARV adherence
Approximately 10 years ago, Ironson and colleagues
found that high baseline depression symptoms pre-
dicted nearly a threefold increase of HIV viral load in
the subsequent 2 years (relative to those with low
depression scores at baseline), even after controlling
for ARV adherence (Ironson et al., 2005). Since the pub-
lication of that study, support has been found for add-
itional pathways between depression and viral load
that do not involve ARV adherence, including cogni-
tive and inflammatory pathways. However, much of
research on the associations between depression and
HIV viral load has focused on single mediators, such
as cognition or ARV adherence, rather than including
and controlling for multiple potential mediators.
HIV and depression: cognition
HIV infection in the central nervous system (CNS) can
lead to cognitive deficits among PLWH, termed HIV-
associated neurocognitive disorder (HAND) (Fellows
et al., 2013). The etiology of HAND is multifactorial
and is thought to include the release of host’s neuro-
toxic substances from infected CNS cells, exposure to
HIV and its neurologically toxic components, cerebro-
vascular abnormalities, CNS inflammation (see below)
and the toxic effects of ARVs. Depression, particularly
major depressive disorder (MDD), also impacts neuro-
psychological testing performance (attention, learning,
memory and processing speed) (McIntyre et al., 2013)
and is associated with changes in the structure and
function of fronto-subcortical brain regions and net-
works (Diener et al., 2012). Given the overlap between
cognitive symptoms of depression and HAND and the
high prevalence of depression among PLWH, there has
been concern that HAND symptoms have been mis-
classified as cognitive symptoms of depression and
vice versa (Hong & Banks, 2015).
Research gap
While some HIV clinicians do assess for and treat men-
tal disorders among their patients, the majority of
PLWH and depression go without treatment, particu-
larly in East Africa, where mental health care is scarce
and HIV is highly prevalent. However, deficits in
depression treatment for care-engaged PLWH in East
Africa are modifiable. The field of global mental health
care implementation research has advanced rapidly
over the past decade, including the development of
strategies to deliver integrated, high-efficacy, evidence-
based depression treatment in East African HIV clinics
using local, non-specialist personnel (Onu et al., 2016).
Extending mental health treatment to care-engaged
PLWH in East Africa would benefit from greater clarity
on how depression affects HIV viral load – a critical
indicator for HIV clinicians. For example, if depression
affects viral load primarily through ARV adherence,
then depression treatment should focus on treatment
engagement and correction of maladaptive health
behaviors (such as non-adherence). On the other
hand, if depression is associated with HIV viral load
independently of ARV adherence, then other potential
global mental health
mediators (e.g. inflammation) may need to be more
fully researched and depression treatment among
PLWH may require a more comprehensive approach.
In this study, we address the research gap by exam-
ining the relationship between depression and viral
load in a robust dataset from the African Cohort
Study (AFRICOS) that allows us to control for adher-
ence and cognitive performance.
Methods
AFRICOS is an ongoing prospective longitudinal
cohort study enrolling HIV-infected adults at 11 HIV
care clinical sites in Kenya, Tanzania, Uganda and
Nigeria. These sites are administered by five
President’s Emergency Plan For AIDS Relief
(PEPFAR) programs (one per country except for two
in Kenya: South Rift Valley and Kisumu West pro-
grams. In light of cultural differences in emotional
expression within sub-Saharan Africa (Sweetland
et al., 2014), we restricted this study to AFRICOS
sites in east Africa (Kenya, Uganda and Tanzania)
and did not include the west African country of
Nigeria. Specifically, we examined baseline data from
East African HIV-infected AFRICOS participants (all
of whom are engaged in HIV care) in Kenya,
Tanzania and Uganda (n = 2307) to evaluate cross-
sectional relationships between depression, cognition,
HIV viral load and ARV adherence.
Study design and participants
HIV-infected clinic clients were randomly selected to
be study participants in a selection scheme that strati-
fied by gender and ARV status and also included
new enrollees to the clinic. A minority were recruited
from other HIV studies performed by our group
locally to facilitate long-term follow-up (n = 245).
Participant recruitment and enrollment for this
study was between 21 January 2013 and 1 March
2017. HIV-infected individuals were eligible if they
were at least 18 years old, receiving HIV care at the
enrolling PEPFAR clinic and consented to data and
specimen collection. We excluded individuals who
were pregnant at enrollment.
Procedures
Participants received a medical history and physical
examination, a broad demographic and behavior ques-
tionnaire, and underwent phlebotomy. Depression
symptoms were evaluated using the Center for
Epidemiologic Studies Depression (CESD) scale,
which was translated into Luganda, Luo and
Kiswahili and performed as part of an interviewer
administered questionnaire. All participants also
performed a brief battery of neuropsychological tests
(see below).
Outcomes
Demographics
Participant age, gender and weekly household income
were determined through chart review.
Income assessment across sites
Purchasing power parity (PPP). We calculated PPP of
weekly household income to standardize and compare
the cost of living across the three country sites. First,
we converted local currency into 2016 USD dollars.
We converted these figures to the market exchange
rate (PPP), multiplying by 0.3 for Uganda and
Tanzania and 0.5 for Kenya.
Depression
We assessed depressive symptoms using the Center for
Epidemiologic Studies Depression Scale (CESD) (Eaton
et al., 2004). The CESD is a 20-item measure that has
been used extensively across high-, middle- and low-
income populations to assess prevalence and severity
of depression. Reponses are recorded on a four point
Likert scale. The instrument has good validity and reli-
ability with a Cronbach’s α of 0.85–0.90 across studies
(Radloff, 1977). A cutoff of 16 is typically used to indi-
cate depression and has good sensitivity and specifi-
city (Lewinsohn et al., 1997). The scale was translated
and adapted using standard procedures including
independent forward and backward translation, fol-
lowed by pilot with test-subjects and incorporation of
feedback. Due to variability in literacy required to
complete the CESD, all items were read to study parti-
cipants. HIV viral load. Viral loads (plasma HIV RVA
levels) were measured using the on-site, Roche
COBAS® Taqman® HIV-1 or Abbott RealTime HIV-1
Viral Load assays.
Treatment status
Participants were identified as being on ARV for all
time-points following the date of first ARV prescrip-
tion through chart review.
Adherence
ARV adherence was determined through self-report,
using the following question: ‘In the past month,
how many days did you miss a dose of your ARVs?’
One month recall of ARV adherence is associated
with objective measures of adherence (see the
‘Limitations’ section) (Buscher et al., 2011). While we
are aware that with modern ARV treatment, viral
global mental health
suppression can be achieved with only 80–84%
adherence (Viswanathan et al., 2015), in light of
emerging data showing that even in the setting of
viral suppression, suboptimal (<100%) adherence cor-
relates with significant clinical outcomes, including
higher inflammation and residual viral replication (Li
et al., 2014; Castillo-Mancilla et al., 2018a, b), we
opted for a stringent definition of adherence, using a
bivariate model assessing adherence over the past
month in which 1 = no missed doses and 0 = doses
missed.
Neuropsychological testing battery
All participants underwent a 30-min neuropsycho-
logical testing battery. Testers were trained on all
neuropsychological tests, certified and re-certified
every 6 months to assure consistent testing across all
sites. The battery consisted of World Health
Organization auditory verbal learning test (AVLT)
trial 1 to assess attention, AVLT sum of trials 1–5 for
learning efficiency and AVLT delayed recall for
memory; Trails A to assess psychomotor speed;
Grooved Pegboard to measure manual dexterity as
well as psychomotor speed and action fluency to assess
verbal performance. Normative data were acquired
from 429 co-enrolled HIV-uninfected individuals
who also sought to care at the same clinics and
stratified to four levels of age and two levels of educa-
tion. We calculated standardized z-scores in a standard
fashion to identify degree of variance from the means
of age and education matched strata. Cognitive im-
pairment on neuropsychological testing was defined
as at least −1 S.D. below the mean on two tests or −2
S.D. below the age and education matched mean on
one test.
Statistical analysis
We analyzed baseline characteristics of HIV-infected
AFRICOS participants enrolled between 21 January
2013 and 1 March 2017, including depression and
demographics by study site, as well ARV treatment
status (on ARVs or not) and associations of key vari-
ables with depression. For those participants who
had been prescribed ARVs, we evaluated the relation-
ship between ARV adherence and depression using
logistic regression to model ARV adherence over the
past month as a bivariate, presenting the results as
odds ratios (ORs) with 95% confidence intervals
(CIs). Given skewness in residual analyses, we used
bootstrapped (10 000 repetitions) linear regression to
model the log10 HIV viral load among the sub-group
of AFRICOS participants who had been on ARVs for
6 months or more. We included both past month
adherence and a dichotomous measure of global
cognitive impairment. We present the results as β coef-
ficients with 95% CIs. Lastly, we conducted explora-
tory analyses of depression symptoms, by performing
sequential bootstrapped (10 000 repetitions) linear
regressions of log10 HIV viral load for AFRICOS parti-
cipants who had been on ARVs for 6 months or more.
Each CESD item for individuals was evaluated in a
separate regression, controlling for ARV adherence
and cognitive impairment. We present the results as
β coefficients with 95% CIs. We also back-transformed
regression estimates and CIs of log10 viral load to
obtain interpretations as percent increase or decrease.
Analyses were conducted using Stata/IC 15.0
(StataCorp, College Station, TX).
Results
Most HIV-infected AFRICOS participants were from
Kenya (63%), female (59%), middle aged (34–63 years
old) (46%), married (59%) and taking ARVs (68%) at
entry. Most reported household incomes of less than
½ international dollar per week. Literacy was high
(89%), and the majority reported completing or par-
tially completing primary school (Table 1). The per-
centage of AFRICOS participants engaged in HIV
care meeting the CESD cutoff for depression: 18%
(Kenya), 25% (Tanzania) and 22% (Uganda).
We evaluated depression (percent with depression
on the CESD) in sub-groups stratified by sex, age,
ARV status and viral load on ARVs for 6 months or
more (Fig. 1). Female sex (p < 0.001), not taking ARVs
(p < 0.001) and detectable viral load (p < 0.001) were
associated with higher proportion of depression rela-
tive to their counterparts in the same category.
Using logistic regression to model ARV adherence,
we found that depression (bivariate) was inversely
associated with ARV adherence (Table 2) for those
individuals who were on ARV treatment (a subset of
the total sample). Those with depression were nearly
twice as likely to report adherence deficits in the past
month, compared with their non-depressed counter-
parts (OR 0.59 [0.39–0.89], p = 0.012). Those with cogni-
tive impairment were more likely to report full ARV
adherence (OR 1.58 [1.09–2.27], p = 0.02).
We used a bootstrapped linear regression to model
log10 HIV viral load among individuals who had
been on ARVs for 6 months or more (a subset of
those on ARVs, Table 3). Covariates included ARV
adherence and cognitive impairment. The log10 of
viral load for those with depression had a 95% CI of
−0.04 to 0.47, p = 0.10. This corresponds to a change
in viral load of 0.91–2.95. Though not significant, the
beta coefficient for depression was 0.21, which is a
60% increase in viral load.
global mental health
Item level analysis of the CESD
Controlling for ARV adherence and cognitive impair-
ment, the log10 HIV viral load was modeled using sep-
arate bootstrapped linear regressions for each CESD
item (Table 4). Associations were found with three
CESD items (appetite, sleep and apathy/energy) of
the CESD (#2 [p = 0.000], #11 [p = 0.01], #20 [p = 0.04]).
Beta coefficients were 0.45, 0.32 and 0.32, respectively,
corresponding to 282, 209 and 209% increases in viral
load.
Discussion
In this large sample of HIV-infected individuals
engaged in treatment in HIV clinics in Kenya,
Tanzania and Uganda, we found a high frequency of
individuals with depression in samples from every
country. Depression has been associated with care
drop out (Krumme et al., 2015). Therefore, the propor-
tion of participants with depression in this study may
be lower than the prevalence among general popula-
tions of PLWH in the region. The prevalence estimate
reported in this study could be viewed as the ‘tip of
the iceberg’ with regard to the prevalence of depres-
sion among PLWH in these countries.
Women, individuals not taking ARVs, and those
who had a detectable viral load on ARVs for 6 months
or more, all had a higher prevalence of depression
compared with their counterparts (Fig. 1). These find-
ings are consistent with studies showing that depres-
sion is typically higher among women compared
with men (Seedat et al., 2008; Albert, 2015) and asso-
ciated with decreased ARV adherence and with
increased HIV viral load (Ironson et al., 2005).
We evaluated the relationships between depression,
ARV adherence and viral load, using regression mod-
els to assess for the effects of cognition. We found that
Table 1. Sample characteristics of HIV-infected AFRICOS adult participants at Kenyan, Tanzanian and Ugandan sites (n = 2307)
Kenya n (%) Tanzania n (%) Uganda n (%) Total n (%)
Totals 1444 (62.6) 388 (16.8) 475 (20.6) 2307 (100)
Taking ARVs
Yes 1130 (78.3) 239 (61.8) 187 (39.4) 1556 (67.5)
No 314 (21.8) 148 (38.2) 288 (60.6) 750 (32.5)
Gender
Female 832 (57.6) 231 (59.5) 282 (59.4) 1345 (58.3)
Male 612 (42.4) 157 (40.5) 193 (40.6) 962 (41.7)
Age
18–33 years 388 (27.4) 122 (32.1) 146 (30.8) 656 (28.9)
34–48 years 658 (46.5) 153 (40.3) 227 (47.9) 1038 (45.8)
49–63 years 275 (19.5) 65 (17.1) 69 (14.6) 409 (18.0)
64+ years 13 (0.9) 14 (3.7) 5 (1.1) 32 (1.4)
Education
Some primary school 496 (35.3) 40 (11.1) 246 (58.7) 782 (35.8)
Completed primary school 345 (24.5) 202 (56.0) 49 (11.7) 596 (27.3)
Some secondary school 198 (14.1) 37 (10.3) 105 (25.1) 340 (15.6)
Completed secondary school 259 (18.4) 56 (15.5) 5 (1.2) 320 (14.6)
Some university 38 (2.7) 3 (0.8) 0 (0) 41 (1.9)
Completed university 46 (3.3) 21 (5.8) 1 (0.2) 68 (3.1)
Completed vocational/training school 25 (1.8) 2 (0.6) 13 (3.1) 40 (1.8)
Ability to read and write 1362 (94.3) 347 (89.4) 356 (75.0) 2065 (89.5)
Marital status
Single 174 (12.0) 79 (20.4) 34 (7.2) 287 (12.4)
Married 917 (63.5) 186 (47.9) 262 (55.3) 1365 (59.2)
Divorced/separated 134 (9.3) 44 (11.3) 134 (28.73 312 (13.5)
Widowed 219 (15.2) 79 (20.4) 44 (9.3) 342 (14.8)
Weekly household income in purchasing powera
<0.5 international dollars/week 71 (4.9) 41 (11.3) 170 (35.3) 282 (12.2)
0.5–1.0 international dollars/week 89 (18.5) 31(8.5) 89 (18.5) 299 (13.0)
>1.0 international dollars/week 1209 (80.9) 291 (80.2) 223 (46.3) 1723 (74.8)
ARV, antiretroviral therapy.
a Income standardized across country sites to international dollars.
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when accounting for demographics and cognitive
impairment, depression remained associated with a
nearly 50% decrease in ARV adherence (Table 2).
Cognitive impairment was unexpectedly associated
with improved ARV adherence. Given that ARV
adherence was assessed through participant recall
and self-report of ARV adherence over the past
month, it is possible that memory impairment may
lead to recall errors and over-reporting of ARV adher-
ence. When objective measures of ARV adherence are
used, cognitive impairment is typically associated
with poorer ARV adherence, relative to those without
cognitive problems (Becker et al., 2011).
We examined correlates of HIV viral load, including
ARV adherence, cognitive impairment and depression
Figure 1. Clinical depression by gender, age, taking ARVs and HIV viral load suppression on ARV in baseline data: HIV+
participants (n = 2307).
Table 3. Bootstrapped multivariate linear regression modeling
log10 viral load among HIV-infected participants on ARV for more
than 6 months, controlling for past month ARV adherence and
cognitive impairment (n = 1380)
β [95% CI] p value
Age −0.01 [−0.02 to −0.01] 0.00
Education −0.02 [−0.07 to 0.03] 0.43
Married −0.10 [−0.27 to 0.06] 0.21
Weekly income converted
to purchasing powera
−0.01 [−0.32 to 0.10] 0.31
Past month ARV adherence
(1 = no missed doses,
0 = missed doses)
−0.44 [−0.71 to −0.17] 0.001
Cognitive impairment
(1 = impaired, 0 = not
impaired)
0.18 [0.01–0.35] 0.04
Depression (1 = CESD ⩾ 16,
0 = CESD < 16)
0.21 [−0.04 to 0.47] 0.10
a Income standardized across country sites; HIV viral load
(VL).
Table 2. Logistic regression modeling ARV adherence over the past
month (1 = no missed doses; 0 = doses missed) (n = 1400)
OR
[95% CI] p value
Age 1.01 [1.00–1.03] 0.10
Education 1.02 [0.91–1.14] 0.70
Married 0.83 [0.59–1.18] 0.30
Weekly income converted to
purchasing powera
1.01 [1.00–1.03] 0.13
Cognitive impairment
(1 = impaired, 0 = not impaired)*
1.58 [1.09–2.27] 0.02
Depression (1 = CESD ⩾ 16 or
0 = CESD < 16)**
0.59 [0.39–0.89] 0.012
a Income standardized across country sites.
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(Table 3), finding that depression had a near significant
relationship with HIV viral load, independently of
ARV adherence and cognitive impairment. Analyses
with individual CESD items revealed that higher levels
of three diverse symptoms (appetite, sleep and apathy/
energy) were associated with viral load independently
of ARV adherence and cognitive impairment – two of
the three were associated with more than doubling of
viral load and one with a near tripling (Table 4).
While there were no CESD items that had indirect rela-
tionships with viral load, it may be that the composite
CESD score is not significantly related to viral load
because the effect of the three significant items is
diluted by the addition of the 17 other items in the
CESD total score calculation. We found that cognitive
impairment was associated with higher viral load, con-
sistent with literature (Tate et al., 2011).
Somatic symptoms
Appetite, sleep and apathy/energy are diverse depres-
sive symptoms, but they are all related to its somatic
manifestations. Given the prevalence of somatic symp-
toms with chronic disease, it is possible that these
symptoms do not reflect a mood disorder, but are
simply the physical manifestations of HIV disease.
The challenges associated with assessment for and
diagnosis of depression in the setting of physical dis-
ease and chronic illness have been the topic of broader
investigation for at least two decades. In 1997, Koenig
and colleagues reported that inclusion of somatic
depressive symptoms when diagnosing major depres-
sion among medically ill patients resulted in high sen-
sitivity for diagnosis, whereas excluding somatic
symptoms led to higher specificity, but missed nearly
50% of MDD cases (Koenig et al., 1997). Currently,
the emerging model is one of reciprocal relationships
between physical and mental disease in which each
increases the risk for the other, coupled with greater
understanding depression as ‘systemic’ disease reflect-
ing inflammatory, hormonal and many other distur-
bances (Katon, 2011; Thom et al., 2019). It is also
important to note that somatic symptoms are more
common among depressed individuals who reside
outside Euro-America, suggesting that a diagnostic
approach that does not discount somatic symptoms
of depression may be even more prudent for the
study’s target population (Lacasse et al., 2014;
Evagorou et al., 2016; Dreher et al., 2017). Finally,
unlike most studies of depression in the setting of
Table 4. Bootstrapped linear regression modeling log10 viral load on each CESD item (separately) among HIV-infected participants on ARV
for more than 6 months, controlling for past month ARV adherence and cognitive impairment (n = 1477–1482)
β [95% CI] p value
Significant items
I did not feel like eating; my appetite was poor (item #2) 0.45 [0.20–0.70] 0.00
My sleep was restless (#11) 0.32 [0.08–0.57] 0.01
I could not get going (#20) 0.32 [0.01–0.64] 0.04
Nonsignificant items
I was bothered by things that usually don’t bother me (item #1) 0.14 [−0.08 to 0.39] 0.20
I felt that I could not shake off the blues even with help from my family or friends (item #3) −0.03 [−0.27 to 0.22] 0.84
I felt I was just as good as other people (item #4) −0.17 [−0.35 to 0.01] 0.06
I had trouble keeping my mind on what I was doing (item #5) 0.08 [−0.22 to 0.41] 0.55
I felt depressed (item #6) 0.03 [−0.20 to 0.27] 0.77
I felt that everything I did was an effort (item #7) 0.08 [−0.05 to 0.20] 0.24
I felt hopeful about the future (item #8) −0.06 [−0.26 to 0.15] 0.60
I thought my life had been a failure (item #9) 0.12 [−0.13 to 0.40] 0.32
I felt fearful (#10) 0.28 [−0.08 to 0.64] 0.13
I was happy (item #12) 0.08 [−0.13 to 0.28] 0.47
I felt hopeful about the future (item #13) 0.22 [−0.11 to 0.56] 0.19
I felt lonely (#14) 0.21 [−0.04 to 0.47] 0.10
People were unfriendly (#15) −0.10 [−0.36 to 0.18] 0.51
I enjoyed life (item #16) −0.10 [−0.25 to 0.06] 0.23
I had crying spells (#17) 0.12 [−0.23 to 0.49] 0.48
I felt sad (item #18) 0.20 [−0.02 to 0.42] 0.08
I felt that people disliked me (item #19) 0.01 [−0.31 to 0.35] 0.91
CESD items are scored on a 0–4 point scale (0 = rarely and 3 =most of the time), except for reverse coded items (#4, 8,
12, 16); HIV viral load (VL).
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physical disease, we included cognitive impairment in
our models given concerns that cognitive symptoms
might reflect the direct effects of the HIV virus on
the CNS rather than depressive symptoms. While
benefitting from the analyses in many ways, it is pos-
sible that this decision also excluded individuals who
were experiencing cognitive deficits secondary to
depression and not HIV infection, reducing the
strength of the relationship between viral load and
depression in the first analyses (Tables 2 and 3) and
potentially obscuring the relationship between HIV
viral load and non-somatic CESD items (Table 4).
Thus, the findings from this study should be under-
stood as identifying depressive symptoms which
remain associated with key HIV outcomes such as
viral load even with quite conservative assumptions
as to the source of the symptoms. Findings should
not be interpreted as indicating that somatic symptoms
are the only relevant depressive features for PLWH in
the target population.
Indeed, one of the key findings of this study is that a
number of depressive symptoms on the CESD are
associated with HIV viral load independently of ARV
adherence and cognitive impairment. These results
suggest that, even if the effects of depression on ARV
adherence could be fully addressed through behavioral
adherence strategies and HIV-related cognitive deficits
remediated, individuals with depression, particularly
those with low appetite, poor sleep and apathy/energy,
would still have an increased HIV viral load.
Limitations
This was a cross-sectional study of baseline data from a
longitudinal study. The results cannot be used to deter-
mine causality. Future research will leverage the longi-
tudinal nature of this study to assess the predictive
value of depression on critical HIV outcomes.
CESD
We note recent analyses of depression in HIV-infected
populations that question the validity of the CESD
when used with heterogeneous samples of diverse
genders (including transgender) and racial groups (n
= 347) (Gay et al., 2016). Given the larger sample size
and greater homogeneity in this East African,
care-engaged study population, we believe the results
to be a valid indication of the associations
among depression, HIV viral load and cognition.
Furthermore, the CESD uses self-report of depressive
symptoms, rather than clinical interview. While the
CESD is found to correlate adequately with clinical
interview in many studies (e.g. Shinar et al., 1986;
Irwin et al., 1999; Moon et al., 2017), there are some
studies in which it is found to have a significant num-
ber of false positive diagnoses (Quiñones et al., 2016;
Vilagut et al., 2016). If the CESD in this study over-
estimated depression, then we would expect the actual
depression prevalence to be lower than reported.
Furthermore, if the CESD results contained false posi-
tives, the relationship between depression and HIV
viral load might be under-estimated by these data.
Given ongoing disagreement regarding the validity
of the CESD, we recommend that validity studies be
undertaken in which CESD results are compared
with a gold-standard, culturally accepted structured
clinical interview, such as the Mini International
Neuropsychiatric Interview (MINI), Major Depressive
Disorder module and clinical exam for other specified
depression and unspecified depression.
Confounders
The number of confounders of the relationship
between depression and HIV viral load that could be
included in this study was limited by the study design,
determined before our engagement with the AFRICOS
team. Confounders are defined as variables that influ-
ence both the dependent and the independent variable
(s), creating the appearance of an association. In par-
ticular, while alcohol and other substance abuse can
be related to ARV adherence and mood disorders,
we selected not to include it in our analyses for the fol-
lowing reasons. Most analyses of the relationships
between depression and substance abuse have found
the interaction to be bi-directional. Furthermore, stud-
ies now advise that co-occurring substance use disor-
ders, do not change the recommendation to treat
depression with evidence-based care (Pettinati et al.,
2013; Baingana et al., 2015; Tolliver & Anton, 2015).
Therefore, while the presence of substance use dis-
order(s) may require the addition of mental health ser-
vices, it does not typically change the clinical
imperative to treat depression. Given the traumatic
experiences of many PLWH in sub-Saharan Africa,
posttraumatic stress disorder (PTSD) is a common
co-morbidity. While measures of PTSD were not ini-
tially included in AFRICOS, during the course of our
work, we were able to add a measure to the
AFRICOS assessment schedule and look forward to
evaluating the findings and the relationships between
PTSD, depression and viral load.
ARV adherence and cognitive impairment
AFRICOS uses a self-report measure of ARV adher-
ence. Self-reported adherence is known to be subject
to recall and social desirability bias, which can lead
to inflated reports of adherence (Castillo-Mancilla &
Haberer, 2018).
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Our analyses of the cognitive battery deployed a bin-
ary assessment of impairment/non-impairment. This
decision did not capitalize on data for individual cog-
nitive domains produced by the study’s cognitive bat-
tery and thus could have resulted in some loss of
precision. However, given that our goal with the cog-
nition variable was to control for the potential overlap
in cognitive deficits seen in both HIV CNS infection
and depression, coupled with the lack of current con-
sensus on the precise effect of either depression or
HIV on specific cognitive function domains, we felt
that the summary measure was the most inclusive
and comprehensive approach.
Conclusions
This study supports the idea that even treatment-
engaged PLWH in sub-Saharan Africa with PEPFAR-
supported care may frequently suffer from depression.
We provide evidence that diverse depressive symp-
toms may be associated with viral load independently
of pathways involved with cognition and ARV
adherence – implying that comprehensive depression
treatment would be necessary to fully address the rela-
tionship between HIV viral load and depression. Given
the recent advances in mental health care delivery
using local non-specialists in sub-Saharan Africa and
PLWH, key next steps include research on scalable,
evidence-based depression treatment with careful
assessment of impact on HIV outcomes.
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